Abbott Rebounds, but a 11% Pullback and Upcoming Earnings Keep the Story Live
Abbott Laboratories heads into Q3 earnings season with a paradox: analysts are more bullish than they've been in years, yet the stock is down 11% over the past month and the CEO has been selling heavily at prices well…